ReviewMolecular psychiatry2006
Subtyping schizophrenia: implications for genetic research.
Review in Molecular psychiatry, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 83 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
83 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Assessing the prevalence of cognitive impairment among Australians with schizophrenia: A systematic review.The Australian and New Zealand journal of psychiatry · 2026Pooled it
- Towards a brain-based predictome of mental illness.Human brain mapping · 2020Pooled it
- Prefrontal cortical thinning links to negative symptoms in schizophrenia via the ENIGMA consortium.Psychological medicine · 2018Pooled it
- Does performance on the standard antisaccade task meet the co-familiality criterion for an endophenotype?Brain and cognition · 2008Pooled it
- Deep learning-based stratification of Schizophrenia Spectrum Disorder from real-world data reveals distinct profiles of common and rare variant genetic signal.medRxiv : the preprint server for health sciences · 2026Article
- Subtyping schizophrenia via machine learning by using structural neuroimaging.Translational psychiatry · 2025Review
- Imaging Biomarker Studies of Antipsychotic-Naïve First-Episode Schizophrenia in China: Progress and Future Directions.Schizophrenia bulletin · 2025Review
- Parkinson's disease and schizophrenia interactomes contain temporally distinct gene clusters underlying comorbid mechanisms and unique disease processes.Schizophrenia (Heidelberg, Germany) · 2024Article
- Schizophrenia in the genetic era: a review from development history, clinical features and genomic research approaches to insights of susceptibility genes.Metabolic brain disease · 2024Review
- Childhood Schizotypy and Adolescent Mental Disorder.Schizophrenia bulletin · 2024Article
- Pathways from developmental vulnerabilities in early childhood to schizotypy in middle childhood.The British journal of clinical psychology · 2023Article
- A growing understanding of the role of muscarinic receptors in the molecular pathology and treatment of schizophrenia.Frontiers in cellular neuroscience · 2023Review
- Attenuated niacin-induced skin flush response in individuals with clinical high risk for psychosis.General psychiatry · 2022Article
- Widespread cortical thinning, excessive glutamate and impaired linguistic functioning in schizophrenia: A cluster analytic approach.Frontiers in human neuroscience · 2022Article
- Integrative omics of schizophrenia: from genetic determinants to clinical classification and risk prediction.Molecular psychiatry · 2022Review
- Identifying subtypes of bipolar disorder based on clinical and neurobiological characteristics.Scientific reports · 2021Article
- Relationship between Dynamic Blood-Oxygen-Level-Dependent Activity and Functional Network Connectivity: Characterization of Schizophrenia Subgroups.Brain connectivity · 2021Article
- Erotomania and phenotypic continuum in a family frameshift variant of AUTS2: a case report and review.BMC psychiatry · 2021Review
- Individual deviations from normative models of brain structure in a large cross-sectional schizophrenia cohort.Molecular psychiatry · 2021Article
- Explainable AI enables clinical trial patient selection to retrospectively improve treatment effects in schizophrenia.BMC medical informatics and decision making · 2021Article
23 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Phenotypic variability and likely extensive genetic heterogeneity have been confounding the search for the causes of schizophrenia since the inception of the diagnostic category. The inconsistent results of genetic linkage and association studies using the diagnostic category as the sole schizophrenia phenotype suggest that the current broad concept of schizophrenia does not demarcate a homogeneous disease entity. Approaches involving subtyping and stratification by covariates to reduce heterogeneity have been successful in the genetic study of other complex disorders, but rarely applied in schizophrenia research. This article reviews past and present attempts at delineating schizophrenia subtypes based on clinical features, statistically derived measures, putative genetic indicators, and intermediate phenotypes, highlighting the potential utility of multidomain neurocognitive endophenotypes.
Indexed as
Identifiers
16801952What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.